SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 539.92 |
| Enterprise Value ($M) | 439.20 |
| Book Value ($M) | 323.53 |
| Book Value / Share | 6.09 |
| Price / Book | 1.67 |
| NCAV ($M) | 304.62 |
| NCAV / Share | 5.74 |
| Price / NCAV | 1.77 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.29 |
| Return on Assets (ROA) | -0.24 |
| Return on Equity (ROE) | -0.25 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 22.78 |
| Current Ratio | 22.78 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 324.57 |
| Assets | 343.48 |
| Liabilities | 19.94 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -104.18 |
| Net Income | -86.48 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -69.77 |
| Cash from Investing | -98.40 |
| Cash from Financing | 202.14 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Vestal Point Capital, LP | 5.40 | ||
| 13G | Commodore Capital Lp | 5.20 | ||
| 13G | Janus Henderson Group Plc | 5.10 | ||
| 13G/A | Fmr Llc | 3.20 | -49.39 | |
| 13D/A | Ra Capital Management, L.p. | 20.10 | 0.07 | |
| 13G | TCG Crossover GP I, LLC | 5.70 | ||
| 13G/A | Biotechnology Value Fund L P | 7.80 | -15.38 | |
| 13G/A | Canaan XI L.P. | 7.40 | -5.22 | |
| 13D/A | Boxer Capital Management, LLC | 5.00 | -37.40 | |
| 13G/A | Nextech Vi Oncology Scsp | 7.70 | 61.04 | |
| 13D/A | Boxer Asset Management Inc. | 0.00 | ||
| 13D/A | Boxer Capital, LLC | 12.40 | 1.33 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 211,635 | 594,588 | 35.59 | |
| 35,974 | 799,441 | 4.50 | |
| 32,848 | 269,766 | 12.18 | |
| 59,478 | 318,799 | 18.66 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TSHA – Taysha Gene Therapies, Inc. | TWST – Twist Bioscience Corporation |
| TXMD – TherapeuticsMD, Inc. | UBX – Unity Biotechnology, Inc. |
| UTHR – United Therapeutics Corporation |
Financial data and stock pages provided by
Fintel.io